CMS has just put on display an interim final rule with comment period to establish special policies to assess the performance year 2017 financial and quality performance of Medicare Shared Savings Program accountable care organizations (ACOs) affected by extreme and uncontrollable circumstances, such as Hurricanes Harvey, Irma, and Maria and the California wildfires. CMS is aligning the Shared Savings Program policy with the extreme and uncontrollable circumstances rules it recently promulgated for the Quality Payment Program. CMS will use the determination of an extreme and uncontrollable circumstance under the Quality Payment Program, including the identification of affected geographic areas and applicable time periods, to trigger the extreme and uncontrollable circumstances policies under the Shared Savings Program. The rule establishes special criteria for determining ACO quality performance scores and modifies the payment methodology under Tracks 2 and 3 to mitigate shared losses owed by ACOs affected by extreme and uncontrollable circumstances during performance year 2017. CMS expects the total increase in shared savings payments and total reduction in shared loss payments for ACOs impacted by this rule in 2017 to be approximately $3.5 million. The regulation is effective January 20, 2018. CMS will accept comments on the rule until February 20, 2018.
The Trump Administration has updated its “Unified Agenda of Regulatory and Deregulatory Actions,” which lists the scope and anticipated timing of pending and future regulations. In releasing the agenda, the Administration highlights its “ongoing progress toward the goals of more effective and less burdensome regulation,” including its plans to finalize three deregulatory actions for every new regulatory action in fiscal year 2018. For instance, the Administration intends to issue a proposed regulation to “remove unnecessary and outdated requirements from the conditions of participation for the Medicare and Medicaid programs for Long-Term Care facilities.” Other planned HHS regulatory and deregulatory actions include, among many others:
- Annual proposed updates to Medicare provider payment rates and policies;
- A proposed CMS rule to establish requirements for third parties that provide financial assistance to patients for premiums to enroll in coverage provided by a qualified health plan;
- A proposed CMS rule to provide Medicare coverage of certain devices under investigation through a clinical research study and certain associated routine care items and services in that research, under the proposed Expedited Coverage of Innovative Technology (ExCITe) coverage pathway;
- A proposed CMS rule to provide an exception to Medicaid fee-for-service access to care documentation requirements for states with high managed care penetration rates;
- A proposed CMS rule to repeal Health Plan Identifier regulations; and
- A proposed HRSA 340B drug pricing program ceiling price and manufacturer civil monetary penalties rule.
More generally, HHS intends to take regulatory actions “aimed at improving service delivery through meaningful information sharing, supporting consumer autonomy and decision-making, and better aligning programs with the most current science.” At the same time, “HHS is committed to streamlining and clarifying its regulations to reduce unnecessary burden” while protecting public health. The Department also intends to continue its focus on addressing fraud, waste and abuse.
The OIG recently issued a report evaluating the accuracy of pharmaceutical manufacturer-reported Medicaid drug rebate program data, including pricing information and FDA classification (e.g., innovator/brand or noninnovator/generic). The OIG determined that the “vast majority” of the drugs in the Medicaid rebate program were classified appropriately in 2016, but about 3% of these drugs (885 drugs) may have been misclassified. The OIG estimates that from 2012 to 2016, Medicaid may have lost $1.3 billion in rebates for 10 potentially-misclassified drugs with the highest total reimbursement in 2016.
In light of these findings, the OIG recommended that CMS: (1) follow up with identified manufacturers to determine whether current classifications are correct; (2) improve the CMS Drug Data Reporting for Medicaid System; and (3) pursue a means to compel manufacturers to correct inaccurate classification data reported to the Medicaid rebate program (either through new legislative authority or a determination that CMS has the authority to suspend potentially-misclassified drugs from Medicaid rebate program participation until the manufacturer corrects all inaccurate information). CMS concurred with the OIG’s recommendations. With regard to the third recommendation, CMS pointed out that it shares oversight responsibility with the OIG, and CMS “encourages OIG to use its enforcement authority to compel manufacturers to correct inaccurate drug classification data reported to the Medicaid drug rebate program.” The OIG responded that while it will continue to pursue penalties against manufacturers where appropriate, it “believes it lacks legal authority to affirmatively pursue penalties for the submission of inaccurate drug classification data.”
On January 9, 2018, CMS is hosting a call to discuss its new low volume appeals settlement option. As previously reported, this option is available for certain Medicare fee-for-service providers, physicians, and other suppliers with fewer than 500 appeals pending at the Office of Medicare Hearings and Appeals and the Medicare Appeals Council at the Departmental Appeals Board. The call will cover provider/supplier eligibility and which pending appeals may be settled. The call will not include a question and answer session, but questions may be submitted in advance. Registration information is available here.
While previous broad Republican efforts to dismantle the Affordable Care Act (ACA) have failed, the GOP tax bill cleared by Congress today has succeeded in effectively repealing the ACA’s individual health insurance mandate. By way of background, the ACA established a penalty for failure to maintain health insurance coverage that provides at least minimum essential coverage, as defined by various ACA regulations. The penalty generally is equal to the greater of (1) 2.5% of income in excess of tax filing thresholds, or (2) a flat dollar threshold (for 2017, the threshold is $695 per adult and $347.50 per child, up to a family maximum of $2,085), subject to certain limitations and exemptions. The “Tax Cuts and Jobs Act” (HR 1) cuts this penalty to zero, effective with respect to health coverage status for months beginning after December 31, 2018. The tax bill does not impact the ACA’s employer insurance coverage responsibilities. President Trump is expected to sign the bill into law in the near future.
The individual insurance mandate was intended to encourage healthier individuals to obtain health insurance, thereby resulting in a more favorable risk pool and lower insurance premiums overall. The Congressional Budget Office (CBO) recently estimated that if the individual mandate were repealed, the number of people with health insurance would decrease by 4 million in 2019 and 13 million in 2027, and average premiums in the individual market would increase by about 10% in most years of the coming decade. Furthermore, federal budget deficits would be reduced by about $338 billion between 2018 and 2027, according to the CBO, mainly due to reduced federal spending on insurance exchange subsidies and Medicaid.
Senate Majority Leader Mitch McConnell has committed to considering legislation to mitigate potential health insurance premium increases caused by the repeal of the individual insurance penalty, including bills to fund cost-sharing-reduction payments and to create high risk pools for individuals with pre-existing conditions. House consideration of such legislation is not assured, however, likely exacerbating uncertainties in the individual insurance market.
This month, Congressional committees held a number of hearings that focused on health policy issues, including the following:
- House Energy & Commerce Committee hearings on the drug supply chain and patient brokering/addiction treatment fraud.
- Senate Health, Education, Labor, and Pensions (HELP) Committee hearings on the cost of prescription drugs and implementation of the 21st Century Cures Act, including a hearing concentrating on the Act’s mental health-related provisions.
- A Senate Judiciary Committee oversight hearing on the “Ensuring Patient Access and Effective Drug Enforcement Act.”
The Food and Drug Administration (FDA) recently released new draft guidance documents to clarify its approach to regulating software as a medical device. The first draft guidance, Clinical and Patient Decision Support Software, addresses provision of the 21st Century Cures Act that exempts certain clinical decision support software from the definition of a medical device. The second guidance, Changes to Existing Medical Software Policies Resulting from Section 3060 of the 21st Century Cures Act, sets forth types of software that the FDA no longer considers medical devices. These guidance documents are analyzed on our sister blog, Life Sciences Legal Update.
The Office of Inspector General (OIG) of the Department of Health and Human Services has released its semiannual report for the period of April 1, 2017, through September 30, 2017. The report also includes aggregated data for all of fiscal year (FY) 2017. For instance, during FY 2017, the OIG achieved:
- $4.13 billion in expected investigative recoveries;
- 881 criminal and 826 civil actions against individuals or entities related to HHS programs; and
- Exclusion of 3,244 individuals and entities from federal health care programs.
In the report, Inspector General Daniel R. Levinson notes the OIG’s growing use of advanced data analytics to detect potential vulnerabilities and fraud trends, which he asserts allows the agency “to target our resources at those areas and individuals most in need of oversight, leaving others free to provide care and services without unnecessary disruption.” Additionally, the OIG takes credit for generating almost $24.4 billion in savings in FY 2017 as a result of its recommendations being included in legislative, regulatory, and other policy decisions.
CMS is extending for another year the Medicare prior authorization program for repetitive, scheduled non-emergent ambulance transport services rendered by ambulance providers in selected states. As previously reported, CMS began testing the three-year Medicare prior authorization model in New Jersey, Pennsylvania, and South Carolina on December 1, 2014. The agency extended the model to the following six locations as of January 1, 2016: Delaware, the District of Columbia, Maryland, North Carolina, Virginia, and West Virginia. While the model was scheduled to end in all states on December 1, 2017, CMS has now extended the program in each of the current model locations; the model will now end in all states on December 1, 2018. According to the CMS notice, prior authorization will not be available for repetitive scheduled non-emergent ambulance transportation services furnished after that date.
On February 13, 2018, CMS is holding a public Town Hall meeting to discuss requests for add-on payments for new medical technologies under the Medicare hospital inpatient prospective payment system (IPPS). Registration details are provided in the meeting announcement.
The Centers for Medicare & Medicaid Services (CMS) has officially cancelled a planned program to require certain hospitals to participate in Medicare episode payment models (EPMs) for acute myocardial infarction, coronary artery bypass graft, and surgical hip/femur fracture treatment procedures furnished in designated areas of the country, along with a Cardiac Rehabilitation (CR) Incentive Payment Model. These programs, which were slated to launch on January 1, 2018, were summarized in previous posts. In a press release, CMS states that not pursuing these models gives it “greater flexibility to design and test innovations that will improve quality and care coordination across the in-patient and post-acute care spectrum.”
In the same rulemaking, CMS also dramatically scaled back the ongoing Comprehensive Care for Joint Replacement (CJR) model. By way of background, this program provides a “bundled” payment to participant hospitals for an “episode of care” for lower extremity joint replacement (LEJR) surgery, covering all services provided during the inpatient admission through 90 days post-discharge (with certain exceptions). The bundled payment is paid retrospectively through a reconciliation process; providers receive regular fee-for-service payments in the interim. The CJR model began April 1, 2016 and runs through 2020.
Most notably, the new rule gives certain hospitals participating in the CJR model a one-time option to choose whether to continue their participation in the model, effective February 1, 2018. This voluntary election option applies to hospitals in 33 of the 67 Metropolitan Statistical Areas (MSAs) selected in the original CJR final rule, along with low volume hospitals and rural hospitals in the remaining 34 mandatory participation MSAs. CMS is designating a one-time participation opt-in period from January 1 – 31, 2018 during which eligible hospitals may opt to continue to participate in CJR. Note, however, that CMS will automatically terminate CJR participation for hospitals in the designated 33 MSAs, along with low volume and rural hospitals, as of February 1, 2018, unless the hospital elects to continue participation in the CJR model. CMS expects the number of hospitals required to participate in CJR to fall from approximately 700 to about 370, and an additional 60 to 80 hospitals to make a voluntary election to continue participation. A list of all current CJR participant hospitals and their status (mandatory or voluntary) is available on the CJR webpage, as is the Voluntary Participation Election Letter Template.
CMS also adopted a number of refinements to CJR model policies, including the following: Continue Reading
A number of Congressional panels have scheduled or held recent hearings on health policy issues, including the following:
- On November 30, 2017, the House Energy & Commerce Committee is holding a hearing on implementation of the 21st Century Cures Act (Cures Act), featuring testimony by National Institutes of Health Director Francis Collins, M.D. and Food and Drug Administration Commissioner Scott Gottlieb, M.D. The panel previously held a hearing on “MACRA and Alternative Payment Models: Developing Options for Value-based Care.”
- The Senate Health, Education, Labor, and Pensions (HELP) Committee held hearings on gene editing technology, the Surgeon General’s perspective on encouraging healthy communities, and health information technology. On November 29, the HELP Committee is considering President Trump’s nomination of Alex Azar to be Secretary of Health and Human Services. The panel has also scheduled a November 30 hearing on “The Front Lines of the Opioid Crisis: Perspectives from States, Communities, and Providers,” along with a December 7 hearing on implementation of the Cures Act.
- The House Oversight and Government Reform Committee held a hearing on combatting the opioid crisis.
The House of Representatives has voted 307 – 111 to approve HR 849, Protecting Seniors’ Access to Medicare Act, to repeal the Independent Payment Advisory Board (IPAB). Under the ACA, the IPAB must submit Medicare spending plans to Congress if projected spending growth exceeds specified targets. IPAB proposals go into effect automatically unless Congress enacts alternative legislation achieving required savings. While IPAB members have not been appointed and the spending trigger has not been met to date, the Congressional Budget Office currently projects that the IPAB authority will be invoked in 2023, 2025, and 2027. The bill now moves to the Senate Finance Committee.
President Trump has signed into law S 920, the National Clinical Care Commission Act, which establishes a national clinical care commission to improve coordination of federal programs that support care for people with complex metabolic syndromes and related autoimmune disorders.
In addition, President Trump signed HR 304, Protecting Patient Access to Emergency Medications Act of 2017. The measure clarifies that emergency medical services professionals may administer controlled substances pursuant to standing or verbal orders in certain circumstances.
The HHS Departmental Appeals Board (DAB) is inviting the public to submit recommendations for precedential Medicare Appeals Council (Council) decisions that will be binding on all CMS, HHS, and Social Security Administration components that adjudicate matters under CMS jurisdiction. The designation of precedential decisions was authorized by regulations adopted earlier this year; the DAB will publish notice of any precedential designations in the Federal Register.
CMS also announced that it will provide a low-volume appeals (LVA) settlement option for certain providers and suppliers with appeals pending at the Office of Medicare Hearings and Appeals (OMHA) and the Council. This option will be available for appellants with fewer than 500 total Medicare Part A or Part B claim appeals pending at OMHA and the Council as of November 3, 2017 with a total billed amount of $9,000 or less per appeal, subject to certain other conditions. Eligible appeals will be settled at 62% of the net allowed amount. In addition, OMHA intends to expand its Settlement Conference Facilitation (SCF) alternative dispute resolution process for certain appellants that are not eligible for the LVA option.
The OIG’s latest compilation of top HHS management and performance challenges flags vulnerabilities in key HHS health and social services programs, including includes the following:
- Ensuring Program Integrity in Medicare (addressing improper payments, fraud, payment policies, health care reforms, and health information technology).
- Ensuring Program Integrity in Medicaid (including compliance with fiscal controls, fraud prevention, and quality of Medicaid data).
- Curbing the Opioid Epidemic (addressing inappropriate prescribing of opioids, fraud and diversion, access to treatment, and misuse of grant funds).
- Improving Care for Vulnerable Populations (addressing substandard nursing home care, hospice care and community-based services problems, and safe services for children).
- Ensuring Integrity in Managed Care and Other Programs Delivered through Private Insurers (including combating fraud, waste, and abuse by health care providers; ensuring compliance by managed care and Part D sponsors; and overseeing the health insurance marketplace).
- Improving Financial and Administrative Management and Reducing Improper Payments (addressing weaknesses in financial management systems, Medicare trust fund issues, improper payments, contracts management, and Digital Accountability and Transparency Act implementation).
- Protecting the Integrity of Public Health and Human Services Grants (ensuring effective Department grants management and grantee program integrity).
- Ensuring the Safety of Food, Drugs, and Medical Devices (including overseeing the drug and medical device supply chain).
- Ensuring Program Integrity and Quality in Programs Serving American Indian and Alaska Native Populations (improving Indian Health Service quality of care, management, and infrastructure; combating fraud; and ensuring adequate internal controls for grant programs).
- Protecting HHS Data, Systems, and Beneficiaries from Cybersecurity Threats (guarding HHS’s data and systems and fostering a culture of cybersecurity beyond HHS).
OIG urges HHS to “be mindful of these challenges and opportunities to address them as it undertakes its efforts to reimagine HHS as part of the Federal Government’s comprehensive plan to reform Government.”
CMS has issued a proposed rule to update the Medicare Advantage (MA) program and Part D prescription drug benefit rules for contract year 2019. The proposed rule would, among many other things:
- Implement a Comprehensive Addiction and Recovery Act (CARA) provision that allows Part D plan sponsors to establish drug management programs that limit at-risk beneficiaries’ access to coverage of opioids to selected prescribers and/or network pharmacies (subject to various limitations);
- Eliminate the “meaningful difference” requirement that limits the variety of plans an MA organization can offer in the same county;
- Modify Part C and Part D Star Ratings rules;
- Clarify the any willing pharmacy standard, including the definitions of mail-order and retail pharmacies;
- Provide for a one month Part D drug transition supply in both the long term care and outpatient settings;
- Update the electronic prescribing standards used by Part D drug plans;
- Authorize CMS to change the data and methodology used to establish maximum out-of-pocket limits;
- Modify Part D tiering exception policy;
- Expedite generic substitutions in certain situations;
- Encourage the use of follow-on biological products for certain beneficiaries;
- Revise requirements related to the review of marketing materials;
- Modify appeals policies;
- Eliminate the prescriber and provider enrollment requirement and establish a “preclusion list” for program integrity risk screening; and
- Streamline various reporting requirements.
CMS also solicits comments on how it could most effectively require Part D drug plan sponsors to pass through at the point of sale a share of the manufacturer rebates they receive — and do so without increasing government costs and without reducing manufacturer payments under the coverage gap discount program. In addition, CMS requests comments on how it could update requirements governing the determination of negotiated prices to ensure that the reported price at the point of sale includes all pharmacy price concessions. CMS discusses in detail the options it is considering, and requests public input on a variety of operational and policy considerations.
CMS will accept comments on the proposed rule until January 16, 2018.
CMS has issued a final rule with comment period making changes to the Quality Payment Program (QPP) for 2018, the second performance year for the reformed physician payment framework mandated by the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). CMS is continuing its “slow ramp-up” of the QPP by building on the transition policies established for 2017. In the 2018 rule, CMS intends to encourage successful QPP participation under either the Merit-based Incentive Payment System (MIPS) or the Advanced Alternative Payment Model (APM) track while reducing burdens on clinicians.
With regard to MIPS participation, the final rule:
- Reweighted the performance category scoring for 2018 as follows: Quality 50%, Cost 10%, Improvement Activities 15%, and Advancing Care Information 25%.
- Increased the performance threshold to 15 points in year two (up from 3 points in 2017).
- Established a Virtual Groups participation option under which solo practitioners and groups of 10 or fewer eligible clinicians that exceed the low-volume threshold may come together “virtually” to participate in MIPS for a one-year performance period.
- Increased the low-volume threshold to less than or equal to $90,000 in Part B allowed charges or less than or equal to 200 Part B beneficiaries (up from $30,000 charges/200 beneficiaries) in order to exclude more practices.
- Provided bonus points for: the treatment of complex patients; use of only the 2015 Edition Certified Electronic Health Record Technology; and clinicians and small practices that submit data on at least one performance category in an applicable performance period.
- Implemented an optional facility-based scoring mechanism for facility-based clinicians, beginning with the 2019 performance year.
- Created hardship exemptions in the Advancing Care Information performance category.
- Added a new improvement activity for clinicians who attest to consulting specified applicable appropriate use criteria (AUC) through a qualified clinical decision support mechanism for outpatient advanced diagnostic imaging services ordered (applicable to clinicians who are early adopters of the Medicare AUC program in the 2018 performance year and for clinicians who begin the Medicare AUC program in future years as specified in separate regulations).
- Promulgated an interim final rule with comment period to address extreme and uncontrollable circumstances MIPS eligible clinicians may face as a result of widespread catastrophic events affecting a region or locale in CY 2017, such as Hurricanes Irma, Harvey and Maria.
CMS also adopted a number of policies affecting APM participants. For instance, the final rule: Continue Reading
The final CMS calendar year (CY) 2018 Medicare home health prospective payment system (HH PPS) rule cuts Medicare payments by 0.4% ($80 million) in 2018 compared to 2017 levels, but CMS did not adopt a more sweeping case mix methodology reform proposal that would have reduced 2019 payments by almost $1 billion.
Under the final rule, CMS applied a 1% update percentage as mandated by the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) for those home health agencies (HHAs) that report required quality data (otherwise the update is decreased by 2 percentage points). This positive update was more than offset by other rate adjustments, however, including a 0.5% reduction due to the sunset of the rural add-on provision and a 0.9% reduction for nominal case-mix coding intensity growth (the last year of a three-year phase in period). The final CY 2018 national, standardized 60-day episode payment rate is $3,039.64, compared to $2,989.97 for 2017; the rate for an HHA that does not submit required quality data is $2,979.45.
As part of the Administration’s recent “Patients Over Paperwork” Initiative, the final rule removed 235 data elements from 33 Outcome and Assessment Information Set (OASIS) assessment instrument items, effective January 1, 2019. CMS also finalized various Home Health Quality Reporting Program refinements involving reconsideration and exception requests and extensions of reporting timeframes. CMS estimates that these provisions will decrease costs for all HHAs by more than $145 million annually. The final rule also, among other things: recalibrated HH PPS case-mix weights; updated the CY 2018 home health wage index using FY 2014 hospital cost report data; and refined requirements under the Home Health Value-Based Purchasing Model.
As previously reported, CMS had considered adopting a new Home Health Groupings Model to focus on clinical characteristics and other patient information rather than the number of therapy visits provided to determine payment, beginning in 2019. CMS did not finalize this proposal, however, in order to take into further consideration public comments regarding the proposal. CMS intends “to further engage with stakeholders to move towards a system that shifts the focus from volume of services to a more patient-centered model.”
CMS has issued final 2018 Medicare clinical laboratory fee schedule (CLFS) rates, which are based on private payer data as mandated by the Protecting Access to Medicare Act of 2014 (PAMA). A companion document explains changes the agency made in response to public comments on the September 2017 preliminary rates and clarifying its methodology. In addition, CMS posted its final determinations regarding the payment basis (crosswalk or gapfill) for new and existing laboratory HCPCS codes for which CMS received no applicable payment information to calculate a private payor rate-based CLFS payment amount.